Skip to Content
Merck
All Photos(1)

Documents

A2487

Sigma-Aldrich

Cotrimoxazole, Ready Made Solution

100 mg/mL in DMSO

Synonym(s):

Trimethoprim-Sulfamethoxazole, TMP-SMX

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H18N4O3 · 5 C10H11N3O3S
CAS Number:
8064-90-2
Molecular Weight:
1556.71
UNSPSC Code:
51102829
NACRES:
NA.85

form

liquid

Quality Level

200

concentration

100 mg/mL in DMSO

color

colorless to faint yellow

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
fungi
parasites

Mode of action

DNA synthesis | interferes

shipped in

dry ice

storage temp.

−20°C

InChI

1S/C14H18N4O3.C10H11N3O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,11H2,1H3,(H,12,13)

InChI key

WZRJTRPJURQBRM-UHFFFAOYSA-N

Application

Cotrimoxazole has been used as an antimicrobial agent.

Biochem/physiol Actions

Cotrimoxazole, a combination of trimethoprim and sulfamethoxazole, interferes with the cellular metabolism of folic acid in the bacterial cell by blocking the biosynthesis of nucleotides. Trimethoprim binds to dihydrofolate reductase (DHFR) which inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF), resulting in an antimicrobial effect. Sulfamethoxazole interferes with the synthesis of nucleic acids in sensitive microorganisms by blocking the conversion of p-aminobenzoic acid to the coenzyme dihydrofolic acid. The net effect of these actions is to inhibit thymidine synthesis which prevents bacterial DNA synthesis.

Packaging

1ml

Preparation Note

prepared using a 1:5 mixture of trimethoprim:sulfamethoxazole

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361fd,H412

Hazard Classifications

Aquatic Chronic 3 - Repr. 2

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nada A Elnadi et al.
Journal of the Egyptian Society of Parasitology, 43(2), 457-462 (2013-11-23)
Pneumocystitis may cause fatal pneumonia in premature, seriously ill infants at intensive care units. The present study evaluated the routine treatment applied at Sohag pediatrics department for neonatal and infantile pneumonia (in NICU & PICU) on PCP and to compare
Milind M Baldi et al.
Journal of bronchology & interventional pulmonology, 20(4), 333-337 (2013-10-29)
Pulmonary alveolar proteinosis (PAP) is a rare disease with worldwide distribution and an estimated incidence of 0.36 cases per million. We report a case of a PAP coexisting with Pneumocystis jiroveci pneumonia and Mycobacterium tuberculosis infection. The patient was treated
Désirée Caselli et al.
The Journal of pediatrics, 164(2), 389-392 (2013-11-21)
To determine whether a simplified, 1-day/week regimen of trimethoprim/sulfamethoxazole is sufficient to prevent Pneumocystis (jirovecii [carinii]) pneumonia (PCP). Current recommended regimens for prophylaxis against PCP range from daily administration to 3 consecutive days per week dosing. A prospective survey of
Heather M Kling et al.
Journal of acquired immune deficiency syndromes (1999), 65(4), 381-389 (2013-10-15)
Despite antiretroviral therapy and trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis, Pneumocystis pneumonia remains an important serious opportunistic infection in HIV-infected persons. Pneumocystis (Pc) colonization in HIV-infected individuals and in HIV-uninfected smokers is associated with chronic obstructive pulmonary disease (COPD). We previously developed a
Gou Hotta et al.
Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 87(5), 596-602 (2013-11-08)
Stenotrophomonas maltophilia (SM) is an important nosocomial pathogen. Due to its intrinsic resistance to various therapeutic drugs, the optimal antimicrobial therapy is often delayed. From January 2005 to September 2012, we retrospectively compared drug susceptibilities, clinical backgrounds, and outcome of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service